Imunon, Inc. Income Statement
IMNN|7 years of annual SEC 10-K data (FY2015-FY2023)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
Imunon, Inc. reported $500,000 in revenue and $36M in net loss for FY2023. Revenue has grown at a 18.9% compound annual rate over the past 8 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2015 |
|---|---|---|---|---|---|---|---|
| Revenue | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $125.0K |
| SG&A Expense | $13.7M | $10.9M | $7.6M | $8.0M | $9.7M | $5.9M | $6.5M |
| R&D Expense | $11.7M | $10.6M | $11.3M | $13.1M | $11.9M | $13.1M | $9.4M |
| Operating Income | -$24.9M | -$21.0M | -$18.5M | -$20.6M | -$21.1M | -$18.5M | -$15.4M |
| Interest Expense | $5.0M | $569.9K | $1.3M | - | - | - | - |
| Income Tax | -$1.6M | -$1.4M | -$1.8M | -$1.8M | -$10.4M | -$10.4M | - |
| Net Income | -$35.9M | -$20.8M | -$21.5M | -$16.9M | -$11.9M | -$20.4M | -$8.3M |
| EPS (Basic) | -$5.03 | -$3.83 | - | - | - | - | - |
| EPS (Diluted) | -$5.03 | - | -$10.08 | -$0.77 | -$0.68 | -$2.72 | -$0.95 |
| Shares Outstanding | 86.6M | 5.8M | 2.7M | 23.3M | 18.8M | 17.3M | 20.0M |
| Operating Margin | -4984.3% | -4201.4% | -3697.3% | -4113.1% | -4213.0% | -3693.7% | -12329.2% |
| Profit Margin | -7179.6% | -4153.9% | -4296.7% | -3370.3% | -2376.7% | -4080.4% | -6601.1% |